Lineage Cell Therapeutics Revenue Growth & History (LCTX)

Lineage Cell Therapeutics reported $14.6M in revenue for fiscal 2025, an increase of 53.24% from the previous fiscal year.

View full Lineage Cell Therapeutics company overview

Lineage Cell Therapeutics annual revenue and growth

Lineage Cell Therapeutics annual revenue

Fiscal yearPeriod endedRevenueChangeGrowth
20252025-12-31$14.6M$5.1M+53.24%
20242024-12-31$9.5M$554,000+6.19%
20232023-12-31$8.9M−$5.8M−39.16%
20222022-12-31$14.7M$10.4M+238.70%
20212021-12-31$4.3M$2.5M+137.73%
20202020-12-31$1.8M−$1.7M−48.05%
20192019-12-31$3.5M−$1.5M−29.53%
20182018-12-31$5.0M$1.5M+44.25%
20172017-12-31$3.5M−$2.5M−41.62%
20162016-12-31$5.9M−$1.1M−15.82%
20152015-12-31$7.0M$1.8M+34.17%
20142014-12-31$5.2M$810,000+18.27%
20132013-12-31$4.4M$518,673+13.25%
20122012-12-31$3.9M−$518,832−11.70%
20112011-12-31$4.4M$726,141+19.58%
20102010-12-31$3.7M$1.8M+92.61%
20092009-12-31$1.9M
About the data

What revenue means

Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.

Primary source

SEC company filings

TickerStat standardizes reported company facts from SEC EDGAR. Derived growth rates use the displayed revenue values and are not company guidance or forecasts.

Review Lineage Cell Therapeutics filings at SEC.gov ↗